Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease

Y S Betty Kim, Eric Jonasch, Ian E. McCutcheon

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Von Hippel-Lindau (VHL) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system (CNS). The most common tumors associated with this disease are histologically benign, slow-growing CNS hemangioblastomas affecting the retina, cerebellum, brainstem, spinal cord ornerve roots. With mean age at diagnosis of 30 years, CNS hemangioblastomas are usually the first manifestation of the disease. Ongoing clinical and radiological surveillance is required, with symptomatic lesions necessitating treatment. As tumor growth is inevitable during the lifetime of most VHL patients, and the multiplicity of tumors may preclude surgical cure, the search for effective therapies is ongoing. Here we provide the first report demonstrating clinical and radiological anti-tumor response using pazopanib, a small molecule multi-receptor tyrosine kinase inhibitor, in a patient with treatment-refractory VHL-associated CNS heman-gioblastoma. Treatment initiation with daily oral pazopanib (800 mg/day) resulted in significant neurologic improvement and radiologic tumor volume reduction.

Original languageEnglish (US)
Pages (from-to)145-149
Number of pages5
JournalTargeted Oncology
Volume7
Issue number2
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Hemangioblastoma
von Hippel-Lindau Disease
Central Nervous System
Neoplasms
Therapeutics
Viscera
Receptor Protein-Tyrosine Kinases
Tumor Burden
Cerebellum
Nervous System
Brain Stem
Retina
Spinal Cord
pazopanib
Growth

Keywords

  • Hemangioblastoma
  • Pazopanib
  • Von Hippel-Lindau disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease. / Kim, Y S Betty; Jonasch, Eric; McCutcheon, Ian E.

In: Targeted Oncology, Vol. 7, No. 2, 06.2012, p. 145-149.

Research output: Contribution to journalArticle

Kim, Y S Betty ; Jonasch, Eric ; McCutcheon, Ian E. / Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease. In: Targeted Oncology. 2012 ; Vol. 7, No. 2. pp. 145-149.
@article{dd09bc21428d436f9757b5c1160cf93f,
title = "Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease",
abstract = "Von Hippel-Lindau (VHL) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system (CNS). The most common tumors associated with this disease are histologically benign, slow-growing CNS hemangioblastomas affecting the retina, cerebellum, brainstem, spinal cord ornerve roots. With mean age at diagnosis of 30 years, CNS hemangioblastomas are usually the first manifestation of the disease. Ongoing clinical and radiological surveillance is required, with symptomatic lesions necessitating treatment. As tumor growth is inevitable during the lifetime of most VHL patients, and the multiplicity of tumors may preclude surgical cure, the search for effective therapies is ongoing. Here we provide the first report demonstrating clinical and radiological anti-tumor response using pazopanib, a small molecule multi-receptor tyrosine kinase inhibitor, in a patient with treatment-refractory VHL-associated CNS heman-gioblastoma. Treatment initiation with daily oral pazopanib (800 mg/day) resulted in significant neurologic improvement and radiologic tumor volume reduction.",
keywords = "Hemangioblastoma, Pazopanib, Von Hippel-Lindau disease",
author = "Kim, {Y S Betty} and Eric Jonasch and McCutcheon, {Ian E.}",
year = "2012",
month = "6",
doi = "10.1007/s11523-012-0214-0",
language = "English (US)",
volume = "7",
pages = "145--149",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "2",

}

TY - JOUR

T1 - Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease

AU - Kim, Y S Betty

AU - Jonasch, Eric

AU - McCutcheon, Ian E.

PY - 2012/6

Y1 - 2012/6

N2 - Von Hippel-Lindau (VHL) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system (CNS). The most common tumors associated with this disease are histologically benign, slow-growing CNS hemangioblastomas affecting the retina, cerebellum, brainstem, spinal cord ornerve roots. With mean age at diagnosis of 30 years, CNS hemangioblastomas are usually the first manifestation of the disease. Ongoing clinical and radiological surveillance is required, with symptomatic lesions necessitating treatment. As tumor growth is inevitable during the lifetime of most VHL patients, and the multiplicity of tumors may preclude surgical cure, the search for effective therapies is ongoing. Here we provide the first report demonstrating clinical and radiological anti-tumor response using pazopanib, a small molecule multi-receptor tyrosine kinase inhibitor, in a patient with treatment-refractory VHL-associated CNS heman-gioblastoma. Treatment initiation with daily oral pazopanib (800 mg/day) resulted in significant neurologic improvement and radiologic tumor volume reduction.

AB - Von Hippel-Lindau (VHL) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system (CNS). The most common tumors associated with this disease are histologically benign, slow-growing CNS hemangioblastomas affecting the retina, cerebellum, brainstem, spinal cord ornerve roots. With mean age at diagnosis of 30 years, CNS hemangioblastomas are usually the first manifestation of the disease. Ongoing clinical and radiological surveillance is required, with symptomatic lesions necessitating treatment. As tumor growth is inevitable during the lifetime of most VHL patients, and the multiplicity of tumors may preclude surgical cure, the search for effective therapies is ongoing. Here we provide the first report demonstrating clinical and radiological anti-tumor response using pazopanib, a small molecule multi-receptor tyrosine kinase inhibitor, in a patient with treatment-refractory VHL-associated CNS heman-gioblastoma. Treatment initiation with daily oral pazopanib (800 mg/day) resulted in significant neurologic improvement and radiologic tumor volume reduction.

KW - Hemangioblastoma

KW - Pazopanib

KW - Von Hippel-Lindau disease

UR - http://www.scopus.com/inward/record.url?scp=84865726638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865726638&partnerID=8YFLogxK

U2 - 10.1007/s11523-012-0214-0

DO - 10.1007/s11523-012-0214-0

M3 - Article

C2 - 22374327

AN - SCOPUS:84865726638

VL - 7

SP - 145

EP - 149

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 2

ER -